Head to Head Review: Second Sight Medical Products (EYES) & Stereotaxis (STXS)

Second Sight Medical Products (NASDAQ:EYES) and Stereotaxis (OTCMKTS:STXS) are both small-cap medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their earnings, profitability, risk, analyst recommendations, valuation, institutional ownership and dividends.

Earnings and Valuation

This table compares Second Sight Medical Products and Stereotaxis’ revenue, earnings per share and valuation.

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Second Sight Medical Products $7.96 million 9.20 -$28.51 million ($0.59) -1.71
Stereotaxis $31.14 million 2.60 -$5.88 million N/A N/A

Stereotaxis has higher revenue and earnings than Second Sight Medical Products.

Profitability

This table compares Second Sight Medical Products and Stereotaxis’ net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Second Sight Medical Products -408.41% -638.26% -279.24%
Stereotaxis -6.30% -15.17% 4.40%

Volatility and Risk

Second Sight Medical Products has a beta of 2.82, meaning that its share price is 182% more volatile than the S&P 500. Comparatively, Stereotaxis has a beta of 1.26, meaning that its share price is 26% more volatile than the S&P 500.

Analyst Ratings

This is a summary of current ratings for Second Sight Medical Products and Stereotaxis, as reported by MarketBeat.com.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Second Sight Medical Products 0 0 1 0 3.00
Stereotaxis 0 0 0 0 N/A

Second Sight Medical Products presently has a consensus price target of $5.00, indicating a potential upside of 397.02%. Given Second Sight Medical Products’ higher possible upside, analysts clearly believe Second Sight Medical Products is more favorable than Stereotaxis.

Institutional and Insider Ownership

10.1% of Second Sight Medical Products shares are owned by institutional investors. Comparatively, 23.2% of Stereotaxis shares are owned by institutional investors. 48.3% of Second Sight Medical Products shares are owned by company insiders. Comparatively, 38.1% of Stereotaxis shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.

Summary

Stereotaxis beats Second Sight Medical Products on 6 of the 11 factors compared between the two stocks.

About Second Sight Medical Products

Second Sight Medical Products, Inc., together with its subsidiaries, develops, manufactures, and markets prosthetic devices to restore functional vision of blind individuals in the United States, Canada, Europe, the Middle East, and Asia. It offers Argus II System, which treats outer retinal degenerations, such as retinitis pigmentosa. The company was formerly known as Second Sight LLC. and changed its name to Second Sight Medical Products, Inc. Second Sight Medical Products, Inc. was founded in 1998 and is headquartered in Sylmar, California.

About Stereotaxis

Stereotaxis, Inc. designs, manufactures, and markets robotic systems and instruments for the treatment of abnormal heart rhythms in the United States and internationally. Its products include Niobe ES robotic system that enables physicians to complete interventional procedures by providing image guided delivery of catheters and guide wires through the blood vessels and chambers of the heart to treatment sites; and Vdrive system, which offers navigation and stability for the diagnostic and therapeutic devices designed to enhance interventional procedures. The company also offers Odyssey solution, a real-time information solution to manage, control, record, and share procedures across networks. In addition, it provides disposables and other accessories, such as QuikCAS automated catheter advancement disposables for the remote advancement of electrophysiology catheters; and CARTO RMT navigation and ablation system, CELSIUS RMT, NAVISTAR RMT, NAVISTAR RMT DS, NAVISTAR RMT THERMOCOOL, and CELSIUS RMT THERMOCOOL irrigated tip diagnostic/ablation steerable tip catheters. Further, the company's disposables and other accessories include V-CAS and V-CAS Deflect catheter advancement systems; and V-loop circular and V-Sono ICE catheter manipulators. The company markets its products through direct sales force, distributors, and sales agents. Stereotaxis, Inc. was founded in 1990 and is headquartered in St. Louis, Missouri.

Receive News & Ratings for Second Sight Medical Products Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Second Sight Medical Products and related companies with MarketBeat.com's FREE daily email newsletter.


Leave a Reply